US 20170197970A1
· Kuehnert
· 2017
[cited by examiner]
EP 2352732A1
· 2011
[cited by applicant]
EP 2483253A2
· 2012
[cited by applicant]
EP 2496556A1
· 2012
[cited by applicant]
EP 2606031A2
· 2013
[cited by applicant]
JP 2017078039A
· 2017
[cited by applicant]
KR 101798840B1
· 2017
[cited by applicant]
WO WO9622293A1
· 1996
[cited by applicant]
WO WO2007113276A1
· 2007
[cited by applicant]
WO WO2008063504A2
· 2008
[cited by applicant]
WO WO2008064255A2
· 2008
[cited by applicant]
WO WO2008123469A1
· 2008
[cited by applicant]
WO WO2008138889A2
· 2008
[cited by applicant]
WO WO2010112116A1
· 2010
[cited by applicant]
WO WO2010115491A2
· 2010
[cited by applicant]
WO WO2011065800A2
· 2011
[cited by applicant]
WO WO2011089400A1
· 2011
[cited by applicant]
WO WO2011133888A1
· 2011
[cited by applicant]
WO WO2013054185A1
· 2013
[cited by applicant]
WO WO2013186159A1
· 2013
[cited by applicant]
WO WO2014110000A1
· 2014
[cited by applicant]
WO WO2014143583A1
· 2014
[cited by applicant]
WO WO2014168824A1
· 2014
[cited by applicant]
WO WO2015163435A1
· 2015
[cited by applicant]
WO WO2015168824A1
· 2015
[cited by applicant]
WO WO2016138472A1
· 2016
[cited by applicant]
WO WO2016193844A1
· 2016
[cited by examiner]
WO WO2018212534A1
· 2018
[cited by applicant]
Allanore et al., “Double-blind, randomized, 8-week placebo-controlled followed by a 16-week open label extension study, with the LPA1 receptor antagonist SAR100842 for patients with diffuse cutaneous systemic sclerosis,…
[cited by applicant]
Aoki et al., “Two pathways for lysophosphatidic acid production,” Biochimica et Biophysica Acta, 1781:513-518 (2008).
[cited by applicant]
Bain et al., “Selective inhibition of autotaxin is efficacious in mouse models of liver fibrosis,” JPET Fast Forward, 1-62 (2016).
[cited by applicant]
Bain et al., “Selective inhibition of autotaxin is efficacious in mouse models of liver fibrosis,” The Journal Of Pharmacology and Experimental Therapeutics, 360:1-13 (2017).
[cited by applicant]
Balupuri et al., “Design, synthesis, docking and biological evaluation of 4-phenyl-thiasole derivatives as autotaxin (ATX) inhibitors,” Bioorganic & Medicinal Chemistry Letters, 1-12 (2017).
[cited by applicant]
Banerjee et al., “Highly potent non-carboxylic acid autotaxin inhibitors reduce melanoma metastasis and chemotherapeutic resistance of breast cancer stem cells,” J Med Chem, 1-69 (2017).
[cited by applicant]
Barbayianni et al., “Autotaxin, a secreted lysophospholipase D, as a promising therapeutic target in chronic inflammation and cancer,” Progress in Lipid Research, (2015).
[cited by applicant]
Bekele et al., “Role of autotaxin and lysophosphatidate in cancer progression and resistance to chemotherapy and radiotherapy,” Clin Lipidol, 7(3):313-328 (2012).
[cited by applicant]
Benesch et al., “Autotaxin is an inflammatory mediator and therapeutic target in thyroid cancer,” Endocrine-Related Cancer, 22(4):593-607 (2015).
[cited by applicant]
Benesch et al., “Coming of Age for Autotaxin and Lysophosphatidate Signaling: Clinical Applications for Preventing, Detecting and Targeting Tumor-Promoting Inflammation,” Cancers, 10(73):1-25 (2018).
[cited by applicant]
Benesch et al., “Inhibition of autotaxin delays breast tumor growth and lung metastasis in mice,” The FASEB Journal, 28(6):2655-2666 (2014).
[cited by applicant]
Benesch et al., “Recent advances in targeting the autotaxin-lysophosphatidate-lipid phosphate phosphatase axis in vivo,” The Journal of Biomedical Research, 30(4):272-284 (2016).
[cited by applicant]
Black et al., “Autotaxin activity increases locally following lung injury, but is not required for pulmonary lysophosphatidic acid production or fibrosis,” The FASEB Journal, 30:2435-2450 (2016).
[cited by applicant]
Bouchareb et al., “Activated platelets promote an osteogenic programme and the progression of calcific aortic valve stenosis,” European Heart Journal, 0:1-13 (2018).
[cited by applicant]
Bouchareb et al., “Autotaxin derived from lipoprotein(a) and valve interstitial cells promotes inflammation and mineralization of the aortic valve,” Circulation, 132:677-690 (2015).
[cited by applicant]
Brooks et al., “Limited fibrosis accompanies triple-negative breast cancer metastasis in multiple model systems and is not a preventive target,” Oncotarget, 9(34):23462-23481 (2018).
[cited by applicant]
Cao et al., “Autocrine lysophosphatidic acid signaling activates β-catenin and promotes lung allograft fibrosis,” J Clin Invest, 127(4):1517-1530 (2017).
[cited by applicant]
Castelino et al., “Amelioration of dermal fibrosis by genetic deletion or pharmacologic antagonism of lysophosphatidic acid receptor 1 in a mouse model of scleroderma,” Arthritis & Rehumatism, 63(5):1405-1415 (2011).
[cited by applicant]
Castelino et al., “An autotaxin/lysophosphatidic acid/interleukin-6 amplification loop drives scleroderma fibrosis,” Arthritis & Rheumatology, 68(12):2964-2974 (2016).
[cited by applicant]
Chu et al., “Autotaxin-LPA receptor axis in the pathogenesis of lung diseases,” Int J Clin Exp Med, 8(10):17117-17122 (2015).
[cited by applicant]
D'Souza et al., “Autotaxin-lysophosphatidic acid signaling contributes to obesity-induced insulin resistance in muscle and impairs mitochondrial metabolism,” Journal of Lipid Research, 1-38 (2018).
[cited by applicant]
Deng et al., “Knowledge-Based Design of Target-focused Libraries Using Protein-Ligand Interaction Constraints,” Journal of Medicinal Chemistry, 49:490-500 (2006).
[cited by applicant]
Dusaulcy et al., “Adipose-specific disruption of autotaxin enhances nutritional fattening and reduces plasma lysophosphatidic acid,” Journal of Lipid Research, 52:1247-1255 (2011).
[cited by applicant]
Extended European Search Report for EP Application No. EP 18785796 dated Dec. 19, 2019.
[cited by applicant]
Farquhar et al., “Autotaxin-lysophosphatidic acid receptor signalling regulates hepatitis C virus replication,” Journal of Hepatology, 1-26 (2017).
[cited by applicant]
Federico et al., “Autotaxin, a lysophospholipase D with pleomorphic effects in oncogenesis and cancer progression,” Journal of Lipid Research, 57:25-35 (2016).
[cited by applicant]
Fotopoulou et al., “ATX expression and LPA signalling are vital for the development of the nervous system,” Developmental Biology, 339:451-464 (2010).
[cited by applicant]
Gan et al., “Blockade of lysophosphatidic acid receptors LPAR1/3 ameliorates lung fibrosis induced by irradiation,” Biochemical and Biophysical Research Communications, 409:7-13 (2011).
[cited by applicant]
Gierse et al., “A Novel Autotaxin Inhibitor Reduces Lysophosphatidic Acid Levels in Plasma and the Site of Inflammation,” The Journal of Pharmacology and Experimental Therapeutics, 334(1):310-317 (2010).
[cited by applicant]
Hashimoto et al., “Lysophosphatidic acid activates Arf6 to promote the mesenchymal malignancy of renal cancer,” Nature Communications, 7(10656):1-11 (2016).
[cited by applicant]
He et al., “Inhibition of autotaxin alleviates inflammation and increases the expression of sodium-dependent glucose cotransporter 1 and Na+/H+ exchanger 3 in SAMP1/Fc mice,” Physiology.org, 1-32 (2018).
[cited by applicant]
Huang et al., “Lysophosphatidic Acid Receptor-2 Deficiency Confers Protection against Bleomycin-Induced Lung Injury and Fibrosis in Mice,” Am J Respir Cell Mol Biol, 49(6):912-922 (2013).
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/KR2018/005516 mailed Aug. 10, 2018.
[cited by applicant]
Kaffe et al., “Hepatocyte autotaxin expression promotes liver fibrosis and cancer,” Hepatology, 65(4):1369-1383 (2017).
[cited by applicant]
Katsifa et al., “The Bulk of Autotaxin Activity is Dispensable for Adult Mouse Life,” PLOS One, 10(11):e0143083 (2015).
[cited by applicant]
King Jr et al., “Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (Inspire): a multicentre, randomised, placeno-controlled trial,” The Lancet, 374:222-228 (2009).
[cited by applicant]
Kritikou et al., “Inhibition of lysophosphatidic acid receptors 1 and 3 attenuates atherosclerosis development in LDL-receptor deficient mice,” Scientific Reports, 6:1-10 (2016).
[cited by applicant]
Kuttruff et al., “Discovery of BI-2545: A novel autotaxin inhibitor that significantly reduces LPA levels in vivo,” ACS Med Chem Lett, 1-8 (2017).
[cited by applicant]
Leblanc et al., “Autotaxin-β interaction with the cell surface via syndecan-4 impacts on cancer cell proliferation and metastasis,” Oncotarget, 9(69):33170-33185 (2018).
[cited by applicant]
Leblanc et al., “Interaction of platelet-derived autotaxin with tumor integrin ?Vβ3 controls metastasis of breast cancer cells to bone,” Blood, 124(20):3141-3150 (2014).
[cited by applicant]
Lee et al., “Autotaxin and LPA1 and LPA5 receptors exert disparate functions in tumor cells versus the host tissue microenviroment in melanoma invasion and metastasis,” Mol Cancer Res, 13(1):174-185 (2015).
[cited by applicant]
Li et al., “Blocking lysophosphatidic acid receptor 1 signaling inhibits diabetic nephropathy in db/db mice,” Kidney International, 91:1362-1373 (2017).
[cited by applicant]
Lin et al., “Lysophosphatidic acid receptor 1 is important for intestinal epithelial barrier function and susceptibility to colitis,” The American Journal of Pathology, 188(2):353-366 (2018).
[cited by applicant]
Maher et al., “Safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG1690, a novel autotaxin inhibitor, to treat idiopathic pulmonary fibrosis (FLORA): a phase 2a randomised placebo-controlled trial,” Lanc…
[cited by applicant]
Mathieu et al., “Pathobiology of Lp(a) in calcific aortic valve disease,” Expert Review of Cardiovascular Therapy, 15(10):797-807 (2017).
[cited by applicant]
Mazzocca et al., “Lysophosphatidic acid receptor LPAR6 supports the tumorigenicity of hepatocellular carcinoma,” Cancer Res, 75(3):532-543 (2015).
[cited by applicant]
Miyasaka et al., “Syntheses of 6-Aminonicotinamide Derivatives and Their Biological Activities,” Yakugaku Zasshi, 95(5):547-551 (1975).
[cited by applicant]
Murai et al., “Analgesic effects of novel lysophosphatidic acid receptor 5 antagonist AS2717638 in rodents,” Neuropharmacology, 1-50 (2017).
[cited by applicant]
Nam et al., “Autotaxin (NPP-2), a Metastasis-enhancing Motogen, Is an Angiogenic Factor,” Cancer Research, 61:6938-6944 (2001).
[cited by applicant]
Nikolaou et al., “Hydroxamic acids constitute a novel class of autotaxin inhibitors that exhibit in vivo efficacy in a pulmonary fibrosis model,” J Med Chem, 61:3697-3711 (2018).
[cited by applicant]
Noble et al., “Pirfenidone in patients with idiopathic pulmonary fibrosis (Capacity): two randomised trials,” The Lancet, 337:1760-1769 (2011).
[cited by applicant]
Noth et al., “A Placebo-Controlled Randomized Trial of Warfarin in Idiopathic Pulmonary Fibrosis,” Am J Respir Crit Care Med, 186(1):88-95 (2012).
[cited by applicant]
Nsaibia et al., “Autotaxin interacts with lipoprotein(a) and oxidized phospholipids in predicting the risk of calcific aortic valve stenosis in patients with coronary artery disease,” Journal of Internal Medicine, 280:5…
[cited by applicant]
Nsaibia et al., “OxLDL-derived lysophosphatidic acid promotes the progression of aortic valve stenosis through a LPAR1-RhoA-NF-kB pathway,” Cardiovascular Research, 113:1351-1363 (2017).
[cited by applicant]
Ohashi et al., “Anti-fibrotic effect of lysophosphatidic acid receptors LPA1 and LPA3 antagonist on experimental murine scleroderma induced by bleomycin,” Fukushima Medical University, 1-28. First published as an accept…
[cited by applicant]
Orosa et al., “The Autotaxin-Lysophosphatidic acid pathway in pathogenesis of rheumatoid arthritis,” European Journal of Pharmacology, (2015). http://dx.doi.org/10.1016/j.ejphar.2015.08.028.
[cited by applicant]
Park et al., “Inhibition of lysophosphatidic acid receptor ameliorates Sjorgen's syndrome in NOD mice,” Oncotarget, 8(16):27240-27251 (2017).
[cited by applicant]
Quan et al., “The critical role and potential target of the autotaxin/lyphosphatidate axis in pancreatic cancer,” Tumor Biology, Mar. 1-11, 2017.
[cited by applicant]
Raghu et al., “An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis,” Am J Respir Crit Care Med, 192(2):e3-e19 (2015).
[cited by applicant]
Raghu et al., “Treatment of Idiopathic Pulmonary Fibrosis with Ambrisentan,” Annals of Internal Medicine, 158(9):641-649 and W-262-W-272 (2013).
[cited by applicant]
Richeldi et al., “Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis,” The New England Journal of Medicine, 360(22):2071-2082 (2014).
[cited by applicant]
Richeldi et al., “Efficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis,” The New England Journal of Medicine, 365(12):1079-1087 (2011).
[cited by applicant]
Saga et al., “A Novel Highly Potent Autotaxin/ENPP2 Inhibitor Produces Prolonged Decreases in Plasma Lysophosphatidic Acid Formation In Vivo and Regulates Urethral Tension,” PLOS One, 9(4):e93230 (2014).
[cited by applicant]
Samadi et al., “Regulation of lysophosphatidate signaling by autotaxin and lipid phosphate phosphates with respect to tumor progression, angiogenesis, metastasis and chemo-resistance,” Biochimie, 93:61-70 (2011).
[cited by applicant]
Sanchez-Marin et al., “Systemic blockade of LPA1/3 lysophosphatidic acid receptors by ki16425 modulates the effects of ethanol on the brain and behavior,” Neuropharmacology, 1-26 (2018). doi: 10.1016/j.neuropharm.2018.0…
[cited by applicant]
Schneider et al., “Bioactive lipids, LPC and LPA, are novel prometastatic factors and their tissue levels increase in response to radio/chemotherapy,” Mol Cancer Res, 12(11):1560-1573 (2014).
[cited by applicant]
Servusova et al., “Alkylamino derivatives of pyrazinamide: Synthesis and antimycobacterial evaluation,” Bioorganic & Medicinal Chemistry Letters, 24:450-453 (2014).
[cited by applicant]
Srikanth et al., “Lysophosphatidic acid and its receptor LPA1 mediate carrageenan induced inflammatory pain in mice,” European Journal of Pharmacology, 1-34 (2018). https://doi.org/10.1016/j.ejphar.2018.10.005.
[cited by applicant]
Stracke et al., “Identification, Purification, and Partial Sequence Analysis of Autotaxin, a Novel Motility-stimulating Protein,” The Journal of Biological Chemistry, 267(4):2524-2529 (1992).
[cited by applicant]
Swaney et al., “A novel, orally active LPA1 receptor antagonist inhibits lung fibrosis in the mouse bleomycin model,” British Journal of Pharmacology, 160:1699-1713 (2010).
[cited by applicant]
Szepanowski et al., “Fingolimod promotes peripheral nerve regeneration via modulation of lysophospholipid signaling,” Journal of Neuroinflammation, 13(143):1-11 (2016).
[cited by applicant]
Tabibian et al., “Absence of the intestinal microbiota exacerbates hepatobiliary disease in a murine model of primary sclerosing cholangitis,” Hepatology, 63(1):185-196 (2016).
[cited by applicant]
Tabuchi, “The autotaxin-lysophosphatidic acid-lysophosphatidic acid receptor cascade: proposal of a novel potential therapeutic target for treating glioblastoma multiforme,” Lipids in Health and Disease, 14(56):1-9 (201…
[cited by applicant]
Tager et al., “The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak,” Nature Medicine, 14(1):45-54 (2008).
[cited by applicant]
Tager, “Autotaxin Emerges as a Therapeutic Target for Idiopathic Pulmonary Fibrosis,” Am J Respir Cell Mol Biol, 47(5):563-565 (2012).
[cited by applicant]
Taghavi et al., “In vitro genetic screen identifies a cooperative role for LPA signaling and c-Myc in cell transformation,” Oncogene, 27:6806-6816 (2008).
[cited by applicant]
Tando et al., “The role of lysophosphatidic acid on airway epithelial cell denudation in a murine heterotopic tracheal transplant model,” Transplantation Direct, 1-11 (2015).
[cited by applicant]
Thalman et al., “Synaptic phospholipids as a new target for cortical hyperexcitability and E/I balance in psychiatric disorders,” Molecular Psychiatry, 23:1699-1710 (2018).
[cited by applicant]
Thirunavukkarasu et al., “Pharmacological characterization of a potent inhibitor of autotaxin in animal models of inflammatory bowel disease and multiple sclerosis,” J Pharmacol Exp Ther, 359:207-214 (2016).
[cited by applicant]
Tigyi, “Aiming drug discovery at lysophosphatidic acid targets,” British Journal of Pharmacology, 161:241-270 (2010).
[cited by applicant]
Toews et al., “Lysophosphatidic acid in airway function and disease,” Biochimica et Biophysica Acta, 1582:240-250 (2002).
[cited by applicant]
Tokumura et al., “Identification of Human Plasma Lysophospholipase D, a Lysophosphatidic Acid-producing Enzyme, as Autotaxin, a Multifunctional Phosphodiesterase,” The Journal of Biological Chemistry, 277(42):39436-3944…
[cited by applicant]
Torzewski et al., “Lipoprotein(a)-associated molecules are prominent components in plasma and valve leaflets in calcific aortic valve stenosis,” JACC: Basic to Translational Science, 2(3):229-240 (2017).
[cited by applicant]
Umezu-Goto et al., “Autotaxin has lysopholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production,” The Journal of Cell Biology, 158(2):227-233 (2002).
[cited by applicant]
Valdes-Rives et al., “Autotaxin-Lysophosphatidic Acid: From Inflammation to Cancer Developmen,” Mediators of Inflammation, (2017), 15 pages. <https://doi.org/10.1155/2017/9173090>.
[cited by applicant]
Van Meeteren et al., “Regulation and biological activities of the autotaxin—LPA axis,” Progress in Lipid Research, 46:145-160 (2007).
[cited by applicant]
Weng et al., “Autotaxin/lysophosphatidic acid signaling mediates obesity-related cardiomyopathy in mice and human subjects,” J Cell Mol Med, 1-9 (2018).
[cited by applicant]
Wunsch et al., “Serum autotaxin is a marker of the severity of liver injury and overall survival in patients with cholestatic liver diseases,” Scientific Reports, 6(30847):1-12 (2016).
[cited by applicant]
Yang et al., “Expression of autotaxin (NPP-2) is closely linked to invasiveness of breast cancer cells,” Clinical & Experimental Metasis, 19:603-608 (2002).
[cited by applicant]
Yun et al., “Diverse roles of LPA signaling in the intestinal epithelium,” Exp Cell Res, 333(2):201-207 (2015).
[cited by applicant]
Zhang et al., “Lysophosphatidic acid receptor antagonism protects against diabetic nephropathy in a type 2 diabetic model,” J Am Soc Nephrol, 28:3300-3311 (2017).
[cited by applicant]
Zhao et al., “Lysophosphatidic acid signaling in airway epithelium: Role in airway inflammation and remodeling,” Cellular Signalling, 21:367-377 (2009).
[cited by applicant]